| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3369417 | Journal of Clinical Virology | 2010 | 5 Pages |
Abstract
Once-weekly emtricitabine led to a higher viral rebound than once-daily monotherapy, but similar immunological changes, thus suggesting a role of M184V in slowing the decrease in CD4% in treatment failing subjects.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Alessandro Soria, Anna Danise, Laura Galli, Simon Tiberi, Elena Seminari, Francesca Cossarini, Alba Bigoloni, Simone Marcotullio, Adriano Lazzarin, Antonella Castagna,